Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study

Overview of attention for article published in International Journal of General Medicine, November 2021

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 5 X posts from 2 X users, with an upper bound of 1,698 followers.

Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung ... https://t.co/WZel5evgSa

Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung ... https://t.co/WZel5evgSa

Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung ... https://t.co/WZel5evgSa

Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung ... https://t.co/WZel5evgSa

New article: Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study https://t.co/HukknnnlqK #lungcancer #oncology https://t.co/XLDerANzsF